Top results

Clinical Article Summaries

Clinical Article Summaries

Read our summaries of timely clinical research to help you stay current with information affecting your day-to-day practice.

Featured

Anhedonia and Cognitive Function in Adults With MDD: Results From the International Mood Disorders Collaborative Project

Clinical Article

Anhedonia and Cognitive Function in Adults With MDD: Results From the International Mood Disorders Collaborative Project

The International Mood Disorders Collaborative Project found a significant correlation between anhedonia and self-reported cognitive impairment in adults with major depressive disorder (MDD), which may help to identify individuals with MDD who are at higher risk of cognitive decline over time.

Read More

Refine this list

Filter

Sort

Anhedonia and Cognitive Function in Adults With MDD: Results From the International Mood Disorders Collaborative Project

Clinical article summary

Anhedonia and Cognitive Function in Adults With MDD: Results From the International Mood Disorders Collaborative Project

The International Mood Disorders Collaborative Project found a significant correlation between anhedonia and self-reported cognitive impairment in adults with major depressive disorder (MDD), which may help to identify individuals with MDD who are at higher risk of cognitive decline over time.
Self-Reported History of Manic/Hypomanic Switch Associated With Antidepressant Use: Data From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Clinical article summary

Self-Reported History of Manic/Hypomanic Switch Associated With Antidepressant Use: Data From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study investigated treatment-emergent risk factors associated with manic and hypomanic episodes in patients with bipolar disorder. The results of this study provide insights into the prevalence of manic/hypomanic switch in patients undergoing antidepressant therapy and may help guide decisions on appropriate management.
Prevalence and Illness Characteristics of the “Mixed Features Specifier” in Adults With Major Depressive Disorder & Bipolar Disorder: Results From the International Mood Disorders Collaborative Project

Clinical article summary

Prevalence and Illness Characteristics of the “Mixed Features Specifier” in Adults With Major Depressive Disorder & Bipolar Disorder: Results From the International Mood Disorders Collaborative Project

The International Mood Disorders Collaborative Project assessed the characteristics and prevalence of mixed features in adults with major depressive disorder (MDD) and bipolar disorder (BP). The results of this study showed that a significant proportion of participants met the criteria for mixed features. These patients experienced more severe depression and other comorbidities, emphasizing the importance of identifying mixed features in MDD and BP patients to help manage their condition appropriately.
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial 

Clinical article summary

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial 

Major depressive disorder (MDD) is a chronic condition that affects millions of Americans. Unfortunately, first-line monotherapy does not adequately address depressive symptoms for some MDD patients. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial set out to determine the relative effectiveness and safety of 3 next-step treatments for MDD in patients who failed to respond adequately to at least 1 antidepressant treatment trial of adequate dose and duration. This clinical article summary shares the key findings of this landmark trial.
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study

Clinical article summary

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study

Major depressive disorder (MDD) is a chronic and disabling condition that affects up to 12% of men and 25% of women. MDD is recurrent, with many patients not achieving complete recovery between depressive episodes. The aim of treatment for MDD is remission, which is associated with improved functioning and prognosis.
Cross-Cultural Adaptation of the Arabic Positive and Negative Syndrome Scale in Schizophrenia: Qualitative Analysis of a Focus Group

Clinical article summary

Cross-Cultural Adaptation of the Arabic Positive and Negative Syndrome Scale in Schizophrenia: Qualitative Analysis of a Focus Group

Studies looking at the diagnosis of schizophrenia are often completed in Western countries. Here, we review the process and importance not only of translation but also of cultural adaptation of a psychiatric rating scale, concentrating on the Positive and Negative Syndrome Scale (PANSS) in patients of Arab descent with schizophrenia. The authors explore issues related to interview structure and cultural sensitivity within varied populations.
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

Clinical article summary

Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial was a 7-year nationwide clinical trial designed to evaluate the efficacy of different medications in patients who did not respond to an initial antidepressant. Rush et al. (2006) evaluated acute and long-term treatment outcomes in patients who participated in the STAR*D trial and identified differences in response and remission rates and time to remission across patients who received up to four sequential treatment steps.
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study and Its Implications for Patients With Chronic Schizophrenia

Clinical article summary

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study and Its Implications for Patients With Chronic Schizophrenia

Lieberman et al reported efficacy and tolerability results from the first phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, which compared first- generation antipsychotic medication with second-generation antipsychotic medication in people with schizophrenia. McEvoy et al and Stroup et al then reported efficacy and tolerability results from the second phase of CATIE, which compared responses to subsequent therapy with a different second-generation antipsychotic in people with schizophrenia who discontinued their previous second-generation antipsychotic.

Welcome To NP Psych Navigator

This website is intended for healthcare professionals inside the United States.
Please confirm that you are a healthcare professional inside the US.

No, I am not US Healthcare professional

You are now leaving NP Psych Navigator

Links to sites outside of NP Psych Navigator are provided as a resource to the viewer. AbbVie Inc accepts no responsibility for the content of non-AbbVie linked sites.

Redirect to:

Please to bookmark content